Given its dual role as both a tumor suppressor and a pro-oncogene, ZFHX3 analysis is invaluable in cancer research. It can be used to identify potential therapeutic targets, stratify patient populations for clinical trials, and monitor treatment response in cancers like prostate, liver, and breast cancer.
Biomarker assays and analytical readouts are critical tools in drug discovery from target validation studies to candidate selection. With years of experience in biomarker analysis and assay design, Creative Biolabs can support your zinc finger homeobox protein 3 (ZFHX3) pipeline by providing comprehensive biomarker analysis. Our ability to evaluate with accuracy and sensitivity is essential in making critical go/no-go study decisions.
Introduction of ZFHX3
The transcription factor ZFHX3 contains 23 zinc-finger domains, four homeodomains, and several other functional motifs. Its subcellular localization, which can be both cytoplasmic and nuclear, significantly influences the cell cycle. Specifically, cytoplasmic ZFHX3 is associated with cell proliferation, whereas nuclear localization promotes cell differentiation.
ZFHX3 exhibits a dual role in cancer, functioning as a tumor suppressor in prostatic carcinogenesis but a promoter of tumor growth in liver cancer. It also regulates the proliferation and differentiation of mammary epithelial cells through interactions with estrogen and progesterone receptors, which are well-established regulators of breast cancer. Furthermore, ZFHX3 mutations have been proposed as a novel predictive marker for non-small cell lung cancer (NSCLC). Its promotion of breast cancer cell proliferation and tumor growth suggests a critical regulatory role in breast carcinogenesis, offering a potential therapeutic target.
Fig.1 Some points of ZFHX3 function research.1
ZFHX3 Analysis Services at Creative Biolabs
ZFHX3 is frequently mutated in metastatic or high-grade human prostate cancers, often leading to loss of function. Creative Biolabs provides comprehensive ZFHX3 analysis services, offering strategic assay validation to ensure accurate and reliable biological data for your drug discovery program. We offer a wide range of study-specific analytical services using platforms such as ELISA, EIA, WB, and HPLC.
Our analytical services are designed to address the full spectrum of your ZFHX3 research needs. Assays include, but are not limited to:
- Quantitative RT-PCR
For precise measurement of ZFHX3 gene expression levels.
- RNA Interference
To study the effects of ZFHX3 knockdown on cellular processes.
- WB, CHIP, IHC Assays
To analyze ZFHX3 protein expression, its binding to DNA, and its localization within tissues.
- Cellular Functional Assays
Including Cell Proliferation Assay, Flow Cytometry Assay, Mammosphere Formation Assay, and Sphere Formation Assay, to evaluate the biological role of ZFHX3 in cell growth and differentiation.
- Tumorigenesis and Cell Line Establishment
To support in vitro and in vivo studies of ZFHX3's role in cancer development.
Service Workflow
Our service workflow is a streamlined process designed for efficiency and accuracy, providing a seamless experience from start to finish.
01Initial Consultation
We begin with a detailed discussion to understand your specific research objectives, as well as the unique characteristics and requirements of your samples.
02Sample and Material Provision
You provide the necessary starting materials, which can include biological samples (e.g., patient tissues, cell lines) or specific molecular reagents critical for the analysis.
03ZFHX3 Analysis Execution
Our expert team executes the analysis using the most appropriate analytical platforms and validated protocols precisely tailored to your project goals.
04Transparent Communication
Throughout the process, we maintain open and clear communication, keeping you informed of progress, key milestones, and any important findings.
05Final Data Delivery
We deliver a comprehensive report containing all raw data, validated results, and a professional interpretation of the findings to provide you with actionable insights that can confidently advance your research.
Applications
Oncology
Diagnostics & Prognostics
Mutations in the ZFHX3 gene are associated with various diseases, including atrial fibrillation and non-small cell lung cancer (NSCLC). Analyzing ZFHX3 can aid in the development of novel diagnostic markers for early detection and prognostic indicators to predict disease progression and patient outcomes.
Drug Discovery
In drug discovery, ZFHX3 analysis can support target validation, help in the screening of small molecule modulators, and assist in the mechanistic study of new drug candidates. This provides a deep understanding of how a compound may interact with ZFHX3-related pathways.
Service Highlights
- Dedicated Expertise: Our team consists of seasoned biologists and project managers with extensive experience in ZFHX3 analysis, ensuring every project is handled with a high degree of scientific rigor.
- Advanced Technology Platforms: We leverage cutting-edge analytical platforms and validated methodologies to provide accurate, reliable, and reproducible data for your biomarker studies.
- Comprehensive Solutions: From initial consultation to final data interpretation, we offer a full suite of services that can be tailored to meet your unique research requirements, regardless of scale or complexity.
- Quality and Efficiency: Our strategic focus on assay validation and streamlined workflows ensures timely delivery of high-quality results, helping you accelerate your research and development timeline.
FAQs
-
What types of biological samples can you analyze for ZFHX3?
We are capable of analyzing a wide range of biological samples, which include, but are not limited to, patient tissue biopsies, blood samples, isolated cell lines, and various animal models. The specific sample type determines the appropriate analysis method, whether it is for gene expression, protein levels, or functional assays.
-
Can you help us design a custom assay for our specific ZFHX3 research question?
Yes, we specialize in providing tailored solutions for ZFHX3 research. We have a team of experts who will collaborate with you to design and develop a custom assay that is specifically validated to address your unique research needs.
-
Is it possible to analyze ZFHX3 in a high-throughput format for large-scale screenings?
Yes, our ZFHX3 analysis services are scalable to accommodate high-throughput screening needs. We can adapt our validated assays to platforms that enable efficient screening of a large number of compounds or samples.
-
Can you provide us with established cell lines for our ZFHX3 functional studies?
Yes, we offer services for the establishment of cell lines for your ZFHX3 functional studies. This includes cell lines with stable ZFHX3 expression or knockdown, which are essential tools for studying its biological role in various cellular contexts.
-
What kind of quality control measures do you have in place for your assays?
We maintain strict quality control measures throughout our entire workflow to ensure the integrity and reliability of the data. This includes using validated reagents, running appropriate positive and negative controls, and performing rigorous data analysis and review.
-
Can you perform ZFHX3 analysis on rare or limited-quantity samples?
Yes, we have specialized techniques and platforms that are optimized for analyzing rare or limited-quantity samples. Our scientists will work with you to develop a strategy that maximizes the data yield from your valuable samples.
Creative Biolabs' scientists will help to design and qualify study-specific biomarker assays and readouts for small and large research animal models. We can transfer and qualify assays or develop them for you. Fast and accurate testing services are available once the assay is developed. If you are interested in our analysis services, please feel free to contact us for more information.
Reference
- Dong, Ge, et al. "ZFHX3 promotes the proliferation and tumor growth of ER-positive breast cancer cells likely by enhancing stem-like features and MYC and TBX3 transcription." Cancers 12.11 (2020): 3415. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cancers12113415
For Research Use Only.
